Loading clinical trials...

Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes | Clinical Trials | Clareo Health

TERMINATEDNA

Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes

NCT02130401•Scion NeuroStim

Summary

This is an open-label, proof of concept study with a single active treatment arm designed to assess whether CVS-based stimulation has a beneficial effect on patients with type 2 diabetes. The primary outcome measure is a difference between pre and post-treatment A1c.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A subject is eligible for the study if all of the following criteria are met:
•Provide written informed consent prior to enrollment.
•Is male or female between 18-70 years old.
•Has been diagnosed with type II diabetes for greater than 12 months.
•Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening:
•* metformin
•* DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin)
•* Pioglitazone
•Has an A l c between 7.5 - 9.0% based upon point of care testing performed at visit 1.
•Currently performs self-monitoring blood glucose checks at least 3 times per week.
+1 more criteria

Exclusion Criteria

•A subject will be excluded if any of the following criteria are met:
•Has Type 1 Diabetes or Gestational Diabetes.
•Is pregnant or planning to become pregnant during the course of the study.
•Current use OR use in the past 6 months of sulfonylureas.
•Current use OR use in the past 6 months of insulin
•History of cardiovascular disease or cerebrovascular disease.
•Any planned surgery during the course of the study.
•Current continuous renal replacement therapy.
•Current oral or injectable steroid use or use within the previous 3 months.
•Previous or current treatment with deep brain stimulation.
+8 more criteria

Locations (1)

UNC Highgate Specialty Center - UNC Diabetes Care Center

Chapel Hill, North Carolina, United States

Key Dates

Start Date

June 1, 2014

Primary Completion Date

May 1, 2015

Completion Date

June 1, 2015

Last Updated

June 6, 2025

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes

Interventions

TNM Device

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

Closed-loop in Adults With Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D